|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biogen, Johnson & Johnson, Lilly, AbbVie, and Celgene could have huge winners on their hands in the near future.
Endo International said shipments of Opana ER will end Sept. 1 as it works to pull the opioid from the market amid safety concerns from regulators.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.